Repository logo
 
Publication

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin

2016-01Journal article Open access
Simple item page
dc.contributor.authorCambier, S
dc.contributor.authorSylvester, RJ
dc.contributor.authorCollette, L
dc.contributor.authorGontero, P
dc.contributor.authorBrausi, MA
dc.contributor.authorvan Andel, G
dc.contributor.authorKirkels, WJ
dc.contributor.authorCalais da Silva, F
dc.contributor.authorOosterlinck, W
dc.contributor.authorPrescott, S
dc.contributor.authorKirkali, Z
dc.contributor.authorPowell, PH
dc.contributor.authorde Reijke, TM
dc.contributor.authorTurkeri, L
dc.contributor.authorCollette, S
dc.contributor.authorOddens, J
dc.date.accessioned2019-11-07T16:19:27Z
dc.date.available2019-11-07T16:19:27Z
dc.date.issued2016-01
dc.description.abstractBACKGROUND: There are no prognostic factor publications on stage Ta-T1 non-muscle-invasive bladder cancer (NMIBC) treated with 1-3 yr of maintenance bacillus Calmette-Guérin (BCG). OBJECTIVE: To determine prognostic factors in NMIBC patients treated with 1-3 yr of BCG after transurethral resection of the bladder (TURB), to derive nomograms and risk groups, and to identify high-risk patients who should be considered for early cystectomy. DESIGN, SETTING, AND PARTICIPANTS: Data for 1812 patients were merged from two European Organization for Research and Treatment of Cancer randomized phase 3 trials in intermediate- and high-risk NMIBC. INTERVENTION: Patients received 1-3 yr of maintenance BCG after TURB and induction BCG. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prognostic factors for risk of early recurrence and times to late recurrence, progression, and death were identified in a training data set using multivariable models and applied to a validation data set. RESULTS AND LIMITATIONS: With a median follow-up of 7.4 yr, 762 patients recurred; 173 progressed; and 520 died, 83 due to bladder cancer (BCa). Statistically significant prognostic factors identified by multivariable analyses were prior recurrence rate and number of tumors for recurrence, and tumor stage and grade for progression and death due to BCa. T1G3 patients do poorly, with 1- and 5-yr disease-progression rates of 11.4% and 19.8%, respectively, and 1- and 5-yr disease-specific death rates of 4.8% and 11.3%. Limitations include lack of repeat transurethral resection in high-risk patients and exclusion of patients with carcinoma in situ. CONCLUSIONS: NMIBC patients treated with 1-3 yr of maintenance BCG have a heterogeneous prognosis. Patients at high risk of recurrence and/or progression do poorly on currently recommended maintenance schedules. Alternative treatments are urgently required. PATIENT SUMMARY: Non-muscle-invasive bladder cancer patients at high risk of recurrence and/or progression do poorly on currently recommended bacillus Calmette-Guérin maintenance schedules, and alternative treatments are urgently required.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEur Urol. 2016 Jan;69(1):60-9.pt_PT
dc.identifier.doi10.1016/j.eururo.2015.06.045pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3346
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.subjectAdjuvants, Immunologicpt_PT
dc.subjectAgedpt_PT
dc.subjectAged, 80 and overpt_PT
dc.subjectBCG Vaccinept_PT
dc.subjectDisease Progressionpt_PT
dc.subjectFemalept_PT
dc.subjectHumanspt_PT
dc.subjectMaintenance Chemotherapypt_PT
dc.subjectMalept_PT
dc.subjectMiddle Agedpt_PT
dc.subjectNeoplasm Recurrence, Localpt_PT
dc.subjectNeoplasm Stagingpt_PT
dc.subjectPrognosispt_PT
dc.subjectRisk Assessmentpt_PT
dc.subjectSurvival Ratept_PT
dc.subjectUrinary Bladder Neoplasmspt_PT
dc.subjectNomogramspt_PT
dc.subjectCHLC UROpt_PT
dc.titleEORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérinpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage69pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage60pt_PT
oaire.citation.titleEuropean Urologypt_PT
oaire.citation.volume69pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Eur Urol 2016 60.pdf
Size:
1.12 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

URO - Artigos